The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

March 5, 2018

Study Completion Date

March 5, 2018

Conditions
Chronic Rhinitis
Interventions
DRUG

Placebo

Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.

DRUG

Guaifenesin

Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.

Trial Locations (1)

23298

Virginia Commonwealth University Children's Hospital of Richmond, Children's Pavilion & Nelson Clinic, Richmond

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Virginia Commonwealth University

OTHER

NCT01364467 - The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study | Biotech Hunter | Biotech Hunter